D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing up-regulation of D2 dopamine receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 1187-1196

  Davidkova, Genoveva ^a   Zhou, Long Wu ^a   Morabito, Mark ^a   Zhang, Sui Po ^a   Weiss, Benjamin ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 PHENYL 1H 3 BENZAZEPINE; COMPLEMENTARY RNA; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PLASMID VECTOR; QUINPIROLE; RACLOPRIDE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; FLUPHENAZINE; FLUPHENAZINE N MUSTARD; FLUPHENAZINE-N-MUSTARD;

ARTICLE; BEHAVIOR; CATALEPSY; CLIMBING; CORPUS STRIATUM; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR UPREGULATION; STEREOTYPY; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; GENE VECTOR; GENETICS; GROOMING; METABOLISM; UPREGULATION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; CATALEPSY; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG TOLERANCE; FLUPHENAZINE; GENETIC VECTORS; GROOMING; HALOPERIDOL; MALE; MICE; QUINPIROLE; RECEPTORS, DOPAMINE D2; RNA, ANTISENSE; STEREOTYPED BEHAVIOR; UP-REGULATION;

EID: 0031596203     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Asper H, Baggiolini M, Burki HR, Lauener H, Ruch W and Stille G (1973) Tolerance phenomena with neuroleptics: Catalepsy, apomorphine stereotypy and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol. Eur J Pharmacol 22:287-294.
2. Butkerait P, Wang H-Y and Freidman E (1994) Increases in guanine nucleotide binding to striatal G proteins is associated with dopamine receptor supersensitivity. J Pharmacol Exp Ther 271:422-428.
3. 1 dopamine receptor mRNA and mu and delta opioid receptors in rat striatum. Neurochem Int 25:355-366.
4. Chouinard G (1991) Severe cases of neuroleptic-induced supersensitivity psychosis: Diagnostic criteria for the disorder and its treatment. Schizophr Res 5:21-33.
5. Coppens HJ, Sebens JB and Korf J (1995) Catalepsy, Fos protein and dopamine receptor occupancy after long-term haloperidol treatment. Pharmacol Biochem Behav 51:175-182.
6. Costall B, Naylor RJ and Nohira V (1978) Climbing behavior induced by apomorphine in mice: A potential model for the detection of neuroleptic activity. Eur J Pharmacol 50:39-50.
7. Creese I, Burt DR and Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483.
8. Davidkova G, Zhang S-P, Zhou L-W and Weiss B (1998) Effects of dopamine receptor antisense RNA expression vectors in the nervous system. In Modulating Gene Expression by Antisense Oligonucleotides to Understand Neural Functioning, ed. by M. McCarthy, Kluwer Academic Publishers, Norwell, MA.
9. Doucet J-P, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, Chen JS, Idara MJST.Jean M, Wigle N, Blanchet P, Grondin R and Robertson GS (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of Fos-B-like proteins in both the rodent and primate striatum. Eur J Neurosci 8:365-381.
10. 2 receptor agonists on rotational behavior and dopamine receptor binding. Eur J Pharmacol 236:385-393.
11. Fields JZ, Lee JM, Gordon JH, Wichlinski LJ and Ritzmann RF (1990) The effects of cyclo (leucyl-glycyl) on nigrostriatal dopaminergic supersensitivity-inhibition of apomorphine-induced climbing. Neuropeptides 16:207-211.
12. 2L dopamine receptors by agonists and antagonists in transfected HEK-293 cells. J Pharmacol Exp Ther 271:1574-1582.
13. 1 receptors. Biochem Pharmacol 32:2921-2927.
14. Goodale DB, Jacobi AGM, Winkler JD and Weiss B (1985) Rapid stereotaxic injections into mouse striatum using a plastic mold. Soc Neurosci 11:772.
15. Grebb JA, Shelton RC and Freed WJ (1997) Diltiazem or verapamil prevents halo-peridol-induced apomorphine supersensitivity in mice. Neural Transm 68:241-255.
16. 2 receptor density in corpus striatum of mice. Acta Pharmacol Toxicol 59:387-391.
17. 2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model. Brain Res Bull 28:697-701.
18. 2A receptor gene: sequence homology with the rat and human genes and expression of alternative transcripts. J Neurochem 57:795-801.
19. Marcotte ER, Sullivan RM and Mishra RK (1994) Striatal G-proteins: Effects of unilateral 6-hydroxydopamine lesions. Neurosci Lett 169:195-198.
20. Martres MP, Constentin J, Baudry M, Marcais H and Protais P (1977) Long-term changes in the sensitivity of pre- and postsynaptic dopamine receptors in mouse striatum evidenced by behavioral and biochemical studies. Brain Res 136:319-337.
21. 2 dopamine receptor reappearance after irreversible receptor blockade. Brain Res 435:147-152.
22. Mileson BE, Lewis MH and Mailman RB (1991) Dopamine receptor 'supersensitivity' occurring without receptor up-regulation. Brain Res 561:1-10.
23. Muller P and Seeman P (1978) Dopaminergic supersensitivity after neuroleptics: Time-course and specificity. Psychopharmacology 60:1-11.
24. 2 dopamine receptors in neuroleptic catalepsy. Eur J Pharmacol 182: 327-334.
25. 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration. Life Sci 26:55-59.
26. Protais P, Costentin J and Schwartz JC (1976) Climbing behavior induced by apomorhine in mice: A simple test for the study of dopamine receptors in the striatum. Psychopharmacology 50:1-6.
27. 2 dopamine receptors. Mol Pharmacol 48:730-737.
28. 2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra. Mol Pharmacol 269:25-33.
29. 2 receptor mRNA in rat striatum by chronic neuroleptic treatment. Eur J Pharmacol 207:165-168.
30. Sanberg PR (1980) Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284:472-473.
31. 4 receptors by 2-fold in rats. Eur J Pharmacol 289:67-72.
32. See RE, Toga AW and Ellison G (1990) Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J Neural Transm 82:93-109.
33. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133-152.
34. 4. Neuropsychopharmacology 7:261-284.
35. 2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse. Neuropharmacology 25:455-463.
36. Staunton DA, Wolfe BB, Groves PM and Molinoff PB (1981) Dopamine receptor changes following destruction of the nigrostriatal pathway: Lack of a relationship to rotational behavior. Brain Res 211:315-327.
37. Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, Mori H and Shiba K (1994) Time course of dopamine 1,2 and serotonin 2 receptor binding of antipsychotics in vivo. Pharmacol Biochem Behav 49:165-169.
38. Tarsy D and Baldessarini RJ (1974) Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 13:927-940.
39. Vasar E, Allikmets L, Soosaar A and Lang A (1990) Similar behavioral and biochemical effects of long-term haloperidol and caerulein treatment in albino mice. Pharmacol Biochem Behav 35:855-859.
40. Weiss B (1997) Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents. CRC Press, Boca Raton, FL.
41. Weiss B, Greenberg L and Clark MB (1984) Physiological and pharmacological modulation of the beta-adrenergic receptor-linked adenylate cyclase system: supersensitivity and subsensitivity. In Dynamics of Neurotransmitter Function, ed. by I. Hanin, pp. 319-329, Raven Press, New York.
42. 2 messenger RNA. Neuroscience 55:607-612.
43. Weiss B, Zhou L-W and Zhang S-P (1996) Dopamine antisense oligodeoxynucleotides as potential novel tools for studying drug abuse. In Antisense Strategies for the Study of Receptor Mechanisms, ed. by R. B. Raffa and F. Porreca, pp. 71-89, Landes Publ. Co., Georgetown, TX.
44. Weiss B, Davidkova G and Zhang S-P (1997a) Antisense strategies in neurobiology. Neurochem Int 31:321-348.
45. 2-mediated behaviors. Neurochem Int 25:355-366.
46. Weiss B, Zhang S-P and Zhou L-W (1997c) Antisense strategies in dopamine receptor pharmacology. Life Sci 60:433-455.
47. Weiss B and Costa E (1967) Adenyl cyclase activity in pineal in pineal gland: Effect of chronic denervation and norepinephrine. Science 156:1750-1752.
48. Wilcox R, Smith R, Anderson J and Riffe W (1980) Apomophine-induced stereotypic cage climbing in mice as a model for studying changes in dopamine receptor sensitivity. Pharmacol Biochem Behav 12:29-33.
49. 2 dopaminergic responses. Psychopharmacology 92:285-291.
50. 2 dopaminergic agonists on rotational behavior in supersensitive mice. J Pharmacol Exp Ther 249:507-516.
51. 2 receptors: behavioral correlates. Nuerosci Lett 161:223-226.
52. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J Pharmacol Exp Ther 271:1462-1470.
53. Zhou L-W, Qin Z-H and Weiss B (1991) Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole. Neuropsychopharmacology 4:47-55.
54. 2 dopamine receptors in mouse striatum. J Pharmacol Exp Ther 268:1015-1023.